title: The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma.
abstract: BACKGROUND
  The purpose of this study was to validate the prognostic effect and the frequency of mutations in the gene expressing epidermal growth factor receptor (EGFR) in lung adenocarcinoma of Japanese patients, on the basis of the new adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society.
  
  
  METHODS
  The new classification was used to reclassify 486 adenocarcinomas. The percentage of each histopathologic subtype and the predominant pattern were determined. EGFR mutation was also investigated. The relationship between these results and clinicopathologic backgrounds was investigated statistically.
  
  
  RESULTS
  No patients with adenocarcinoma in situ or minimally invasive adenocarcinoma died within the follow-up periods, followed by patients with lepidic predominant. Patients with papillary or acinar predominant, or invasive mucinous adenocarcinoma, showed almost similar overall survival (OS). The patients with solid predominant and micropapillary predominant showed the worst OS. Multivariate analysis showed that the new classification was an independent predictor of OS. The frequency of EGFR mutation was adenocarcinoma in situ (62%), minimally invasive adenocarcinoma (60%), lepidic (77%), acinar (49%), papillary (50%), solid (28%), micropapillary (43%), and invasive mucinous adenocarcinoma (0%).
  
  
  CONCLUSIONS
  This new adenocarcinoma classification is a very useful predictive marker to plan and determine a therapeutic strategy for lung adenocarcinoma.
authors: Department of Diagnostic Pathology, Yamagata Prefectural Central Hospital, Yamagata, Japan. Electronic address: nyanagaw@ypch.gr.jp.
authors: Naoki
authors: N
authors: Yanagawa
authors: Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
authors: Satoshi
authors: S
authors: Shiono
authors: Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
authors: Masami
authors: M
authors: Abiko
authors: Department of Diagnostic Pathology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
authors: Shin-ya
authors: SY
authors: Ogata
authors: Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
authors: Toru
authors: T
authors: Sato
authors: Department of Diagnostic Pathology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
authors: Gen
authors: G
authors: Tamura
mesh_terms: D000230:Adenocarcinoma / Q000145:classification / Q000235:genetics* / Q000401:mortality*; D000077192:Adenocarcinoma of Lung; D000368:Aged; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification / Q000235:genetics* / Q000401:mortality*; D008297:Male; D009154:Mutation; D011379:Prognosis; D015272:Pulmonary Medicine; D012189:Retrospective Studies; D012955:Societies, Medical; D015996:Survival Rate
chemical_list: D066246:ErbB Receptors